Non-small cell lung cancer (NSCLC) is the most common malignancy worldwide, with up to 50% of patients developing brain metastases (BMs) in their disease course. Patients with driver gene mutations even appear to have a much higher incidence of BMs. The treatment options included chemotherapy, immunotherapy, radiotherapy, surgery, and tyrosine kinase inhibitor (TKI) treatment alone or in combination for patients with driver gene mutations. Based on progression in various treatment modalities, the efficacy of BMs from NSCLC has also been greatly improved. However, many patients still die from BMs, and many questions regarding therapeutic modalities need to be clarified. For example, why patients with driver gene mutations have a higher incidence of BMs, what are the optimal therapeutic modalities for BMs from NSCLC patients with or without driver gene mutations, what are the optimal radiation modalities for multiple BMs, how can cerebral radiation necrosis be prevented, and whether brain radiotherapy plus immunotherapy can trigger abscopal effects in or out of the brain. Therefore, every aspect of the therapeutic modalities for BMs from NSCLC needs to be optimized.
This Research Topic aims to collect articles focusing on optimizing treatment strategies for BMs from NSCLC with or without driver gene mutations, including the efficacy and toxicity of chemotherapy, immunotherapy, radiotherapy, surgery, and TKI treatment. We also focus on the underlying molecular mechanisms for the incidence of BMs, response and toxicities to the different treatments, and treatment resistance. Any original clinical, translational, and preclinical research and review focusing on but not limited to the following aspects are welcome.
1) Treatment strategy optimization for BMs from NSCLC with or without driver gene mutations.
2) Radiation modality optimization for multiple BMs, especially for single-isocenter volumetric modulated arc therapy technology.
3) The prevention of cerebral radiation necrosis and imaging studies focused on distinguishing between tumor progression and cerebral radiation necrosis.
4) The toxicities of TKI treatment for the BMs of NSCLC with driver gene mutations, especially for the cognitive impairment induced by TKI treatment.
5) The efficacy and toxicity of immunotherapy alone or combined with other treatments, including chemotherapy, radiotherapy, and surgery, for BMs from NSCLC, and the possibility of abscopal effects triggered by immunotherapy in or out of the brain.
6) The underlying molecular mechanisms for the incidence of BMs, response and toxicities to the different treatments, and treatment resistance.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
All Guest Editors declare no competing interests with regards to the Research Topic subject.
Non-small cell lung cancer (NSCLC) is the most common malignancy worldwide, with up to 50% of patients developing brain metastases (BMs) in their disease course. Patients with driver gene mutations even appear to have a much higher incidence of BMs. The treatment options included chemotherapy, immunotherapy, radiotherapy, surgery, and tyrosine kinase inhibitor (TKI) treatment alone or in combination for patients with driver gene mutations. Based on progression in various treatment modalities, the efficacy of BMs from NSCLC has also been greatly improved. However, many patients still die from BMs, and many questions regarding therapeutic modalities need to be clarified. For example, why patients with driver gene mutations have a higher incidence of BMs, what are the optimal therapeutic modalities for BMs from NSCLC patients with or without driver gene mutations, what are the optimal radiation modalities for multiple BMs, how can cerebral radiation necrosis be prevented, and whether brain radiotherapy plus immunotherapy can trigger abscopal effects in or out of the brain. Therefore, every aspect of the therapeutic modalities for BMs from NSCLC needs to be optimized.
This Research Topic aims to collect articles focusing on optimizing treatment strategies for BMs from NSCLC with or without driver gene mutations, including the efficacy and toxicity of chemotherapy, immunotherapy, radiotherapy, surgery, and TKI treatment. We also focus on the underlying molecular mechanisms for the incidence of BMs, response and toxicities to the different treatments, and treatment resistance. Any original clinical, translational, and preclinical research and review focusing on but not limited to the following aspects are welcome.
1) Treatment strategy optimization for BMs from NSCLC with or without driver gene mutations.
2) Radiation modality optimization for multiple BMs, especially for single-isocenter volumetric modulated arc therapy technology.
3) The prevention of cerebral radiation necrosis and imaging studies focused on distinguishing between tumor progression and cerebral radiation necrosis.
4) The toxicities of TKI treatment for the BMs of NSCLC with driver gene mutations, especially for the cognitive impairment induced by TKI treatment.
5) The efficacy and toxicity of immunotherapy alone or combined with other treatments, including chemotherapy, radiotherapy, and surgery, for BMs from NSCLC, and the possibility of abscopal effects triggered by immunotherapy in or out of the brain.
6) The underlying molecular mechanisms for the incidence of BMs, response and toxicities to the different treatments, and treatment resistance.
Please note: manuscripts consisting solely of bioinformatics or computational analysis of public genomic or transcriptomic databases that are not accompanied by validation (independent cohort or biological validation in vitro or in vivo) are out of scope for this section and will not be accepted as part of this Research Topic.
All Guest Editors declare no competing interests with regards to the Research Topic subject.